|
2. Etiologie
|
|
|
Breast Cancer Risk May Rise After Childbirth, but Is Still Low [NY Times]
|
|
|
|
|
|
To
show that the risk is small, Dr. Nichols explained that in women
between the ages of 41 and 50 who had given birth in the previous three
to seven years, the study found that 2.2 percent developed breast
cancer, while in those who had not had babies, the figure was 1.9
percent. The increase in risk lasted for about 20 years. No rise in risk
was detected in women who had babies before age 25.
|
|
|
|
|
|
|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
3.4 Chimioprévention
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
Breast Cancer Subtype-Specific Polygenic Risk Scores Identified [Genome Web]
|
|
|
|
|
|
By
bringing together array-based genotyping data for nearly 94,100 breast
cancer cases and more than 75,000 controls enrolled through dozens of
Breast Cancer Association Consortium studies, the researchers came up
with several potential PRS focused on overall breast cancer risk or the
risk of developing specific breast cancer subtypes.
|
|
|
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.4 Traitements - Economie
|
|
|
Cure ‘futures’ offer a way to pay for million-dollar medicines [STAT]
|
|
|
|
|
|
You
could buy a futures contract as a call option for the right to purchase
a therapy that has not yet been invented but is close. Individuals
would pay something, say $250 a year for illustration purposes, for the
right to buy a disease-specific cure at a fixed affordable amount, one
that their health plan would likely cover.
|
|
|
|
|
|
|
5.6.7 ESMO - Immunothérapies
|
|
|
|
|
|
|
|
Esmo-IO – Astrazeneca plays its tumour mutation burden card [Vantage]
|
|
|
|
|
|
The
greatest interest will fall on the TMB analysis. In subjects defined as
TMB-high Astra claimed a six-month survival benefit for the combo,
which it described as very exciting albeit exploratory. Speaking to
Vantage today Mika Sovak, Astra’s vice-president of immuno-oncology,
stressed that the TMB analysis would need to be confirmed in a future
trial.
|
|
|
|
|
|
|
5.7 SABCS
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
6.8 Communication
|
|
|
|